What is Ofatumumab?

Ofatumumab (Ofatumumab) is a new type of anti-CD2O monoclonal antibody that can be used alone or in combination. When used alone, it can treat relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Ofatumumab has been used to treat chronic lymphocytic leukemia (CLL) and can be used in combination with chlorambucil to treat patients with previously untreated CLL. ; It can also be used in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed CLL; it can also be used with fludarabine and alemtuzumab for the treatment of patients with refractory CLL; for patients who have a complete or partial response after receiving at least two courses of treatment for relapsed or progressive CLL, ofatumumab can be used for extended treatment.